Glenmark Pharmaceuticals LimitedNSE: GLENMARK

Glenmark Pharmaceuticals Limited Press Release Feb 14 2025

· Issued by Glenmark Pharmaceuticals Limited via NSE India

Filed with NSE · · 2 pages · English

Summary by 6ix AI

This solution is bioequivalent and therapeutically equivalent to the reference drug Xalatan. The launch reflects Glenmark's commitment to expanding its offerings in the ophthalmic market.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

On 6ix: 6ix.com/news/glenmark-pharmaceuticals-limited-press-release-feb-14-2025

Watch Glenmark Pharmaceuticals' latest callGlenmark Pharmaceuticals (NSE:GLENMARK) Q2 2026 Earnings Call · Replay · Nov 6

Glenmark Pharmaceuticals Limited on 6ix

In the deck

Earlier from Glenmark Pharmaceuticals

Later from Glenmark Pharmaceuticals

All Glenmark Pharmaceuticals news releases